| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
261.92(M) |
| Last
Volume: |
1,607,087 |
Avg
Vol: |
2,316,426 |
| 52
Week Range: |
$0.449 - $1.67 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
36,653 |
73,355 |
186,690 |
544,022 |
| Total Sell Value |
$24,924 |
$42,909 |
$121,964 |
$1,484,432 |
| Total People Sold |
3 |
3 |
6 |
11 |
| Total Sell Transactions |
3 |
6 |
15 |
39 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2021-08-16 |
4 |
S |
$13.83 |
$105,965 |
D/D |
(7,662) |
212,803 |
|
-12% |
|
| Northcott John |
SVP & Chief Commercial Officer |
• – – |
2021-08-16 |
4 |
S |
$13.83 |
$85,635 |
D/D |
(6,192) |
200,915 |
|
-12% |
|
| Wilson Mark Andrew |
SVP & General Counsel |
• – – |
2021-08-16 |
4 |
S |
$13.83 |
$26,415 |
D/D |
(1,910) |
72,900 |
|
-12% |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2021-08-16 |
4 |
S |
$13.83 |
$184,478 |
D/D |
(13,339) |
137,822 |
|
-12% |
|
| Robin Howard W |
President & CEO |
• • – |
2021-08-16 |
4 |
S |
$13.83 |
$159,252 |
D/D |
(11,515) |
424,123 |
|
-12% |
|
| Chess Robert |
Director |
– • – |
2021-07-22 |
4 |
AS |
$16.80 |
$1,529 |
D/D |
(91) |
280,573 |
|
-32% |
|
| Chess Robert |
Director |
– • – |
2021-07-22 |
4 |
OE |
$13.80 |
$1,256 |
D/D |
91 |
280,664 |
|
- |
|
| Chess Robert |
Director |
– • – |
2021-07-21 |
4 |
AS |
$16.81 |
$59,238 |
D/D |
(3,524) |
280,573 |
|
-33% |
|
| Chess Robert |
Director |
– • – |
2021-07-21 |
4 |
OE |
$13.80 |
$48,631 |
D/D |
3,524 |
284,097 |
|
- |
|
| Chess Robert |
Director |
– • – |
2021-07-20 |
4 |
AS |
$16.80 |
$35,381 |
D/D |
(2,106) |
280,573 |
|
-31% |
|
| Chess Robert |
Director |
– • – |
2021-07-20 |
4 |
OE |
$13.80 |
$29,063 |
D/D |
2,106 |
282,679 |
|
- |
|
| Wilson Mark Andrew |
SVP & General Counsel |
• – – |
2021-05-17 |
4 |
S |
$18.30 |
$35,081 |
D/D |
(1,917) |
74,810 |
|
-2% |
|
| Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2021-05-17 |
4 |
S |
$18.30 |
$144,533 |
D/D |
(7,898) |
251,098 |
|
-2% |
|
| Robin Howard W |
President & CEO |
• • – |
2021-05-17 |
4 |
S |
$18.30 |
$211,548 |
D/D |
(11,560) |
435,638 |
|
-2% |
|
| Northcott John |
SVP & Chief Commercial Officer |
• – – |
2021-05-17 |
4 |
S |
$18.30 |
$111,356 |
D/D |
(6,085) |
207,107 |
|
-2% |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2021-05-17 |
4 |
S |
$18.30 |
$245,055 |
D/D |
(13,391) |
151,161 |
|
-2% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2021-05-17 |
4 |
S |
$18.30 |
$569,331 |
D/D |
(31,111) |
235,065 |
|
-2% |
|
| Chess Robert |
Director |
– • – |
2021-05-12 |
4 |
AS |
$19.34 |
$154,720 |
D/D |
(8,000) |
280,573 |
|
-5% |
|
| Chess Robert |
Director |
– • – |
2021-05-12 |
4 |
OE |
$13.80 |
$110,400 |
D/D |
8,000 |
288,573 |
|
- |
|
| Chess Robert |
Director |
– • – |
2021-04-14 |
4 |
AS |
$18.98 |
$151,840 |
D/D |
(8,000) |
280,573 |
|
-27% |
|
| Chess Robert |
Director |
– • – |
2021-04-14 |
4 |
OE |
$13.80 |
$110,400 |
D/D |
8,000 |
288,573 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2021-02-16 |
4 |
S |
$22.37 |
$257,143 |
D/D |
(11,495) |
447,198 |
|
23% |
|
| Wilson Mark Andrew |
SVP & General Counsel |
• – – |
2021-02-16 |
4 |
S |
$22.37 |
$48,610 |
D/D |
(2,173) |
76,727 |
|
23% |
|
| Northcott John |
SVP & Chief Commercial Officer |
• – – |
2021-02-16 |
4 |
S |
$22.37 |
$343,558 |
D/D |
(15,358) |
213,192 |
|
23% |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2021-02-16 |
4 |
S |
$22.37 |
$261,841 |
D/D |
(11,705) |
164,552 |
|
23% |
|
909 Records found
|
|
Page 5 of 37 |
|
|
0.14 (10.61%) 
